Actively Recruiting
A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Led by Eisai Co., Ltd. · Updated on 2026-01-23
5000
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
CONDITIONS
Brief Title
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All participants who are treated with lecanemab in routine clinical practice
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Eisai trial site 2
Hiroshima, Japan
Actively Recruiting
2
Eisai trial site 3
Kyoto, Japan
Actively Recruiting
3
Eisai trial site 1
Tokyo, Japan
Actively Recruiting
Research Team
E
Eisai Inquiry Service.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here